Congratulations to OPCI for their 10th New York meeting! It was a privilege to participate in and support their promotion of training and innovation in the interventional cardiology community. We're excited to see how the HyperVue Imaging System and #DeepOCT+NIRS can play a part.
SpectraWAVE, Inc.
Medical Equipment Manufacturing
Bedford, MA 6,026 followers
Improving coronary artery disease outcomes with optical and computational insights.
About us
SpectraWAVE, located in Bedford, Mass., is a privately held medical device company founded in 2017 to provide unrivaled optical and computational insights to improve the treatment and outcomes for patients with coronary artery disease (CAD). CAD, the buildup of plaque in the wall of the arteries that supply blood to the heart, affects 18.2 million adults age 20 and older. In CAD patients that undergo percutaneous stent placement, it is estimated that one in five patients experience adverse events within two years. SpectraWAVE’s state of the art HyperVue™ Imaging System combines next generation DeepOCT™ images and near infrared spectroscopy (NIRS) with workflows optimized for the cardiac catheterization lab. The HyperVue Imaging System is intended for the imaging of coronary arteries and is indicated in patients who are candidates for transluminal interventional procedures. The NIRS capability of the system is intended for the identification of patients and plaques at increased risk of major adverse cardiac events. For more information and complete indications for use, please visit www.spectrawave.com.
- Website
-
http://www.spectrawave.com
External link for SpectraWAVE, Inc.
- Industry
- Medical Equipment Manufacturing
- Company size
- 11-50 employees
- Headquarters
- Bedford, MA
- Type
- Privately Held
Locations
-
Primary
Get directions
12 Oak Park Dr
Bedford, MA 01730, US
Employees at SpectraWAVE, Inc.
-
Steven Weinstein
Venture Investor, CEO and Life Science Executive
-
Hisham Salem, PMP
Program Management | Operations | Med Devices | Hardware | Systems | Imaging | Robotics
-
Sinan Geoffrey Biro
-
Vivek Walimbe
Chief Operating Officer @ SpectraWAVE, Inc. | Product & Operations Executive | Transformation Leader | Innovation | Med Tech
Updates
-
Thank you to Dr. Ziad Ali for his presentation of DeepOCT+NIRS in the Best of JSCAI Session at SCAI 2024. Learn more by visiting the SpectraWAVE team at SCAI 2024 booth #411 to see a demo, or visiting our website http://spectrawave.com!
-
-
📢Is it time to consider treating non-flow limiting plaques at increased risk of MACE? PREVENT trial results published recently in The Lancet demonstrated improved clinical outcomes at 2 years when performing preventative PCI on high-risk plaques vs. medical therapy alone. Preventative PCI on non-flow limiting plaques identified by intravascular imaging resulted in: ⬇️ Target Vessel Failure (TVF) at 2 years and 7 years ⬇️ Composite of death from any cause, any MI, and any revascularization at 2 years Learn more about how SpectraWAVE’s HyperVue Imaging System can identify patients and plaques at increased risk of major adverse cardiac events at www.spectrawave.com Read full publication here: https://lnkd.in/eURyEZKK
-
Thrilled to share our CEO Eman Namati presenting SpectraWAVE’s HyperVue Imaging System and the unique value of our #DeepOCT+NIRS technology for simple, fast and effective coronary stent planning and optimization. #LSIUSA24
Eman Namati, SpectraWAVE - AI-Enabled Intravascular Imaging | LSI USA '24
https://www.youtube.com/
-
Our CEO Eman Namati will be presenting today at #LSIUSA24, Medtech's premier partnering event. Join him in Track 1 at 5 PM this evening to learn more about SpectraWAVE! #LSIAlumni #medtech
-
-
📣 New Publication out now in JSCAI highlighting clinical experience and unique value of the HyperVue Imaging System, SpectraWAVE’s intravascular imaging platform! The publication showcases DeepOCT+NIRS imaging in various plaque morphologies, and head-to-head image comparisons to other commercial products. Congratulations to all the authors! Read the full publication here: https://lnkd.in/ekrNK6QX
-
-
❗ A landmark meta-analysis published in The Lancet featuring data from 15,964 patients in 22 trials, demonstrates reduction of cardiac death, MI, ST, TLF, and all cause death, when using intravascular imaging-guided PCI vs angio alone. Compared to angio-guided PCI, utilizing intravascular imaging (OCT or IVUS) resulted in: 29% ⬇ in Target Lesion Failure (TLF) 45% ⬇ in cardiac death 25% ⬇ in all-cause mortality 17% ⬇ in Myocardial Infarction (MI) 48% ⬇ in the risk of definite or probable stent thrombosis (ST) This data is significant for patients and physicians who care for them. The HyperVue Imaging System was designed with both patients and physicians in mind, combining next generation DeepOCT + NIRS images with simplified workflows for confident clinical decision making. To learn more about our product, please visit: www.spectrawave.com https://lnkd.in/egacphv6
Intravascular imaging-guided coronary drug-eluting stent implantation: an updated network meta-analysis
thelancet.com
-
SpectraWAVE is excited to announce two new additions to the Board of Directors – David Neustaedter of Deerfield Management, and Ramin Mousavi of CathWorks. At this pivotal point in the company’s tenure, as we commercialize the HyperVue Imaging System in the United States, we look forward to leveraging the wealth of venture and commercial MedTech experience from each of these incredible leaders.
-
-
SpectraWAVE, Inc. reposted this
It’s time for #TCT2023! Come by Booth 2237 to learn more about the future of intravascular imaging with the HyperVue Imaging System! #ImageWithoutCompromise #DeepOCT
-